3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
pembrolizumab
23
Gemcitabine
9
Nivolumab
7
Carboplatin
7
Trastuzumab
6
Early Intervention, Educational
6
avelumab
5
atezolizumab
5
Docetaxel
5
Cisplatin
5
cemiplimab
4
Standard of Care
4
Psychiatric Rehabilitation
4
Paclitaxel
4
Methods
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Fluorouracil
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
pertuzumab
3
fludarabine
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
enadenotucirev
×
Gastrointestinal
×
Clear all
NCT02028442
2020-03-12
EVOLVE
Akamis Bio
Phase 1/2
Completed
61 enrolled